Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina

Lendoire, Javier; Moro, Michele; Andriani, Oscar; Grondona, J.; Gil, O.; Raffin, G.; Silva, J.; Bracco, Ricardo; Podestá, Gustavo; Valenzuela, Cristian D.; Imventarza, Oscar; Pekolj, Juan; Santibañés, Eduardo de

doi:10.1080/13651820701769701

Cited by 61 publications

(82 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os índices de sobrevida nas últi-mas séries tem se aproximado dos índices publicados nas de metástases CR e tem variado de 24 até 37 % em cinco anos (22,37,38). A sobrevida global de 20 % em cinco anos da presente série, tanto no Grupo 1 (CR) quanto no Grupo 2 (NCRNE) foi similar a de diversas outras séries previamente descritas (1,2,14,37,39).…”

Section: Tabela 5 -Características Dos Sobreviventes Livres De Doençaunclassified

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Costa

Horta

Henriques

et al. 2009

Rev bras. colo-proctol.

View full text Add to dashboard Cite

INTRODUÇÃOAtualmente, a ressecção cirúrgica de metástases hepáticas de etiologia colorretal é a única modalidade com intenção curativa ou de prolongamento da sobrevida. Em séries mais recentemente publicadas, a sobrevida dos pacientes submetidos à sua ressecção completa (R0) tem variado de 25 % até 55 % em cinco anos (1-3). Em contrapartida, quando indivíduos com disseminação hepática são submetidos a tratamento quimioterápico exclusivo, raramente alcançam mais do que três anos de sobrevida (4).

show abstract

Section: Tabela 5 -Características Dos Sobreviventes Livres De Doençaunclassified

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Costa

Horta

Henriques

et al. 2009

Rev bras. colo-proctol.

View full text Add to dashboard Cite

show abstract

“…Three of the studies were multicentre efforts [32,33,42]. The 22 single-centre studies contained 694 patients, i.e.…”

Section: Studies Of Liver Resection (N=25)mentioning

confidence: 99%

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Bergenfeldt

Jensen

Skjoldbye

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Aim : To analyze surgical treatment of breast cancer liver metastases (BCLM) regarding selection criteria, outcome and prognostic parameters.Methods : We searched Embase and Medline for all studies published 1999-2010.Results : Resection was associated with a median survival (MOS) of 20-67 months and 5-year survival of 21-61%. Local ablation also had a favourable outcome; MOS was 30-60 months and and 5-year survival 27-41%. Regarding selection, no specific limits regarding the number and size of BCLM can be given. Features of the primary breast cancer (BC) was not significant for the prognosis. Microscopically radical (R0) resection is a positive prognostic factor, while the effects of disease interval, hormone receptor status and response to preoperative chemotherapy were divergent. The presence of EHD had a negative effect on survival in some studies, but failed to have so in other studies.Conclusions: Surgical therapy may benefit a subset of patients with BCLM. Resection may be indicated, if an RO-resection can be done with a low risk of mortality. Liver resection in the presence of extrahepatic disease remains controversial, while patients with BCLM and bone metastases could possibly be managed differently than other EHD.

show abstract

“…En nuestra serie, únicamente dos factores han presentado significación en relación a una supervivencia inferior, la presencia de ganglios positivos en la cirugía del tumor primario y la presencia de enfermedad extrahepática en la cirugía de las MH, en concordancia con otros trabajos [19][20][21][22] .…”

Section: Discussionunclassified

Metástasis Hepáticas De Origen No Colorrectal Ni Neuroendocrino: Tratamiento en Un Hospital De Segundo Nivel

et al. 2015

Rev Chil Cir

View full text Add to dashboard Cite

liver metastases from non-colorectal non-neuroendocrine tumors. treatment in a hospital of second level introduction: Surgical treatment of liver metastases is broadly accepted for colorectal and neuroendocrine tumors. However, the approach to liver metastases of other origins is not well established. The objective is the evaluation of factors that might be associated with better or worse perioperative outcomes (morbidity and mortality) and survival of patients with non-colorectal, non-neuroendocrine liver metastases (nCnnLM) treated surgically in a second level hospital. material and methods: A prospective study of patients with nCnnLM treated surgically or with radiofrequency was completed in San Cecilio University Hospital of Granada, between March 2003 and June 2013. The statistical analysis was made with IBM-SPSS version 21. Statistical significance was set at p ≤ 0.05. Survival data were analyzed by Kaplan-Meier´s method. results: Twenty-two patients with 26 surgeries were analyzed, 19 liver resections, 6 radiofrequency treatments and 1 combined case with surgery and radiofrequency. Operatory mortality was 0% and overage mortality was 23.1%. Univariate analysis only showed statistical significance in two of the factors, presence of positive lymphatic nodes during the surgery of the primary tumor and presence of extra-hepatic disease. Accumulated survival was 81%, 66% and 52% at 1, 2 and 3 years respectively. conclusions: Despite the fact of treating together in the same group several different tumors, the surgical treatment of nCnnLM (with or without radiofrequency) has an acceptable survival rate. Thus, they can be treated with safety when we use a multidisciplinary approach to these patients.

show abstract

Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina

Abstract: Liver resection is an effective treatment for NCRNNE liver metastases; it gives satisfactory long-term survival especially in metachronous disease, in patients with metastases from urogenital and breast tumors and when R0 procedures can be performed.

Cited by 61 publications

References 21 publications

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Metástasis Hepáticas De Origen No Colorrectal Ni Neuroendocrino: Tratamiento en Un Hospital De Segundo Nivel

Contact Info

Product

Resources

About